Background: Direct-acting Antivirals (DAAs) dramatically improve the treatment of hepatitis C virus (HCV) infections; however, the treatment of HCV in young children with chronic kidney disease is controversial because of possible adverse effects. Case summary: We report a case of sustained remission of a 9-year-old Egyptian girl with end stage kidney disease on regular dialysis was diagnosed as having chronic hepatitis C, genotype 1a. She was treated with Paritaprevir/ ritonavir/ombitasvir and dasabuvir for 12 weeks. Conclusion: Our case showed a high safety margin, efficacy and tolerability in Hemodialysis-dependent patient under the age of 12. Confirmation of these clinical observations in large clinical studies may help improve morbidity and decrease mortality outcome in pediatric with chronic kidney disease.
